Compound 17: Pharmacological Data for a Dual URAT1/GLUT9 Inhibitor

Qian Yang published a dataset on figshare in May 2026 detailing the development of a novel thienopyrimidine derivative for gout and hyperuricemia. The dataset likely contains experimental results for 46 novel polycyclic pyrimidine derivatives, including IC50 values for URAT1 and GLUT9 inhibition, pharmacokinetic profiles, and efficacy data from animal models. The data supports compound 17 as a promising dual inhibitor with enhanced efficacy and safety.

Use Cases

• Compare IC50 values for URAT1 and GLUT9 inhibition based on the reported potency data.
• Analyze pharmacokinetic profiles and bioavailability based on the reported F% values.
• Evaluate urate-lowering efficacy based on the reported serum uric acid reduction percentage in mice.
• Assess safety profiles based on the reported acute toxicity dose threshold.

Strengths

• Dataset includes specific IC50 values (4.01 μM for URAT1, 1.60 μM for GLUT9) for a lead compound.
• Contains concrete efficacy metrics, such as a 82.4% reduction in serum uric acid levels in hyperuricemic mice.
• Provides pharmacokinetic data with bioavailability (F%) comparisons (33.71% vs 20.13%).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (264.4 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Scaffold hopping and structure-guided design of 46 novel derivatives.

Freshness

Last updated 2026-05-06 16:08:13; freshness should be verified.